Moderna was the first US company to put a vaccine into human trials © Getty Images

Be the first to know about every new Coronavirus story

The first US Covid-19 vaccine trial has shown positive results, after Moderna reported its potential vaccine boosted the immune system of participants to the same or higher levels of protection as patients who had recovered from the disease. 

The Boston-based biotech company announced the interim results from the early stage trial on Monday morning, showing the vaccine candidate known as mRNA-1273 was safe and well tolerated by participants, with only minor side-effects. 

Stéphane Bancel, Moderna’s chief executive, said he could not have expected better data.

The news boosted sentiment on Wall Street, where the S&P 500 US benchmark equity index closed more than 3 per cent higher. Shares in Moderna closed 20 per cent higher at $80, giving the company a market valuation of almost $30bn.

Taking advantage of the surge in interest on the results, Moderna launched a $1.25bn share issue after trading closed, with Morgan Stanley as the book runner. The company said it would use the funds mainly to expand manufacturing capacity for the potential Covid-19 vaccine. Any remaining capital would go to fund clinical development and drug discovery in other areas.

Recent market moves have been accentuated by hopes for coronavirus treatments. In April, positive data that an antiviral drug made by Californian drugmaker Gilead might be able to help patients recover more quickly lifted the S&P 500 to close almost 2 per cent higher.

Moderna was the first US company to put a vaccine into human trials, racing after the receipt of the genetic code of the vaccine to create the first vials in just 42 days.

Its messengerRNA approach allows it to effectively programme a vaccine — but a vaccine using this method has not yet been approved by any regulator. 

There were just 45 participants for the early stage, and the data on antibodies was only available for eight of those.

The study participants, aged between 18 and 55, received two doses of the vaccine. Two weeks following the second dose, those on the lowest dose showed the same level of antibodies seen in recovered patients. The group on an increased dose showed higher levels.

“I’m really thrilled,” Mr Bancel told the Financial Times. “What is really special about mRNA technology is we have pushed it to a place where more antibodies are made than a natural infection so it should provide a long immunity.” 

He believed Moderna could start a large phase three trial in July, as the phase two trial was starting shortly. The third trial will need to include thousands of participants, to demonstrate safety and efficacy across a large population.

Mr Bancel said even if the vaccine showed an efficacy rate as low as 60 or 70 per cent, it could be useful in stopping the replication rate of the virus. The third trial would probably be conducted at sites around the world, as it was hard to predict where an outbreak of Covid-19 would occur at that time.

That larger final trial could give results by the end of the year. Mr Bancel said regulators were moving fast and pointed to recent comments by US health secretary Alex Azar that a vaccine could be approved by the end of the year.

Unlike most vaccines, which show the body’s immune system an attenuated version of the virus, messengerRNA translates a protein from the virus into human cells and shows it to the B cells that secrete antibodies. Antibodies wane over time, so the more antibodies that are created at the start, the more likely that they remain effective for longer.

Editor’s note

The Financial Times is making key coronavirus coverage free to read to help everyone stay informed. Find the latest here.

Tal Zaks, Moderna chief medical officer, said the results showed that even lower doses elicited an “immune response of the magnitude caused by natural infection”.

The results — plus data from a study in mice — have allowed Moderna to focus the next trials on the lower end of the dose scale. 

Side-effects in the early phase of the trial were those that are common for many vaccines: some people experience redness at the site of injection and chills.

“These data substantiate our belief that mRNA-1273 has the potential to prevent Covid-19 disease,” he said.


Get alerts on Coronavirus pandemic when a new story is published

Copyright The Financial Times Limited 2021. All rights reserved.
Reuse this content (opens in new window)

Follow the topics in this article